Genetics of Dementia

Henry L. Paulson; Indu Igo

doi:10.1055/s-0031-1299784

Seminars in Neurology, Inhaltsverzeichnis

Semin Neurol 2011; 31(5): 449-460
DOI: 10.1055/s-0031-1299784

Genetics of Dementia

Henry L. Paulson¹ ^, ² , Indu Igo¹

¹Department of Neurology, University of Michigan, Ann Arbor, Michigan
²University of Michigan, Alzheimers Disease Center, Ann Arbor, Michigan

Abstract

ABSTRACT

Genetic factors are now recognized to play an important role in most age-related dementias. Although other factors, including aging itself, contribute to dementia, in this review the authors focus on the role of specific disease-causing genes and genetic factors in the most common age-related dementias. They review each dementia within the context of a genes/environment continuum, with varying levels of genetic versus environmental influence. All major classes of dementia will be discussed but greatest attention will be given to the most common dementia, Alzheimer's disease, for which several new genetic factors were recently identified.

KEYWORDS

Amyloid - frontotemporal dementia - dementia with Lewy bodies - neurodegeneration - genetic risk factors

Volltext

Referenzen

REFERENCES

1 Bertram L, Lill C M, Tanzi R E. The genetics of Alzheimer disease: back to the future. Neuron. 2010; 68 (2) 270-281
2 Van Broeckhoven C. The future of genetic research on neurodegeneration. Nat Med. 2010; 16 (11) 1215-1217
3 Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet. 2010; 19 (R1) R12-R20
4 Kim J, Basak J M, Holtzman D M. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009; 63 (3) 287-303
5 Green R C, Roberts J S, Cupples L A REVEAL Study Group et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med. 2009; 361 (3) 245-254
6 Ashe K H, Zahs K R. Probing the biology of Alzheimer's disease in mice. Neuron. 2010; 66 (5) 631-645
7 Kim D, Tsai L H. Bridging physiology and pathology in AD. Cell. 2009; 137 (6) 997-1000
8 Thinakaran G, Koo E H. Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008; 283 (44) 29615-29619
9 LaFerla F M. Pathways linking Abeta and tau pathologies. Biochem Soc Trans. 2010; 38 (4) 993-995
10 Ittner L M, Ke Y D, Delerue F et al.. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010; 142 (3) 387-397
11 Cruchaga C, Kauwe J S, Mayo K et al.. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet. 2010; 6 (9) pii: e1001101
12 Fagan A M, Head D, Shah A R et al.. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009; 65 (2) 176-183
13 Holtzman D M. Cerebrospinal fluid beta-amyloid 42, tau, and P-tau: confirmation now realization. Arch Neurol. 2009; 66 (12) 1552-1553
14 Hu W T, Chen-Plotkin A, Arnold S E et al.. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol. 2010; 119 (6) 669-678
15 Jack Jr C R, Knopman D S, Jagust W J et al.. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010; 9 (1) 119-128
16 Jagust W J, Landau S M, Shaw L M Alzheimer's Disease Neuroimaging Initiative et al. Relationships between biomarkers in aging and dementia. Neurology. 2009; 73 (15) 1193-1199
17 Morris J C, Roe C M, Grant E A et al.. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009; 66 (12) 1469-1475
18 Vemuri P, Wiste H J, Weigand S D Alzheimer's Disease Neuroimaging Initiative et al. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology. 2010; 75 (2) 143-151
19 Sperling R A, Aisen P S, Beckett L A et al.. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7 (3) 280-292
20 Bertram L, McQueen M B, Mullin K, Blacker D, Tanzi R E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007; 39 (1) 17-23
21 Colhoun H M, McKeigue P M, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet. 2003; 361 (9360) 865-872
22 Harold D, Abraham R, Hollingworth P et al.. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009; 41 (10) 1088-1093
23 Lambert J C, Heath S, Even G European Alzheimer's Disease Initiative Investigators et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009; 41 (10) 1094-1099
24 Seshadri S, Fitzpatrick A L, Ikram M A CHARGE Consortium et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010; 303 (18) 1832-1840
25 Hollingworth P, Harold D, Sims R Alzheimer's Disease Neuroimaging Initiative et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011; 43 (5) 429-435 10.1038/ng.803
26 Bettens K, Sleegers K, Van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet. 2010; 19 (R1) R4-R11
27 Yerbury J J, Poon S, Meehan S et al.. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 2007; 21 (10) 2312-2322
28 Kirszbaum L, Bozas S E, Walker I D. SP-40,40, a protein involved in the control of the complement pathway, possesses a unique array of disulphide bridges. FEBS Lett. 1992; 297 (1–2) 70-76
29 Thambisetty M, Simmons A, Velayudhan L et al.. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry. 2010; 67 (7) 739-748
30 Calero M, Rostagno A, Frangione B, Ghiso J. Clusterin and Alzheimer's disease. Subcell Biochem. 2005; 38 273-298
31 Braskie M N, Jahanshad N, Stein J L et al.. Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults. J Neurosci. 2011; 31 (18) 6764-6770
32 Krych-Goldberg M, Atkinson J P. Structure-function relationships of complement receptor type 1. Immunol Rev. 2001; 180 112-122
33 Zanjani H, Finch C E, Kemper C et al.. Complement activation in very early Alzheimer disease. Alzheimer Dis Assoc Disord. 2005; 19 (2) 55-66
34 Eikelenboom P, Veerhuis R, Scheper W, Rozemuller A J, van Gool W A, Hoozemans J J. The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm. 2006; 113 (11) 1685-1695
35 Rogers J, Li R, Mastroeni D et al.. Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging. 2006; 27 (12) 1733-1739
36 Brouwers N, Van Cauwenberghe C, Engelborghs S et al.. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol Psychiatry. 2011; ; March 15 [Epub ahead of print]
37 Tebar F, Bohlander S K, Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol Cell. 1999; 10 (8) 2687-2702
38 Koo E H, Squazzo S L. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem. 1994; 269 (26) 17386-17389
39 Carey R M, Balcz B A, Lopez-Coviella I, Slack B E. Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta protein. BMC Cell Biol. 2005; 6 30
40 Harel A, Wu F, Mattson M P, Morris C M, Yao P J. Evidence for CALM in directing VAMP2 trafficking. Traffic. 2008; 9 (3) 417-429
41 Sakamuro D, Elliott K J, Wechsler-Reya R, Prendergast G C. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat Genet. 1996; 14 (1) 69-77
42 Wigge P, McMahon H T. The amphiphysin family of proteins and their role in endocytosis at the synapse. Trends Neurosci. 1998; 21 (8) 339-344
43 Meunier B, Quaranta M, Daviet L, Hatzoglou A, Leprince C. The membrane-tubulating potential of amphiphysin 2/BIN1 is dependent on the microtubule-binding cytoplasmic linker protein 170 (CLIP-170). Eur J Cell Biol. 2009; 88 (2) 91-102
44 Tanaka N, Abe-Dohmae S, Iwamoto N, Yokoyama S. Roles of ATP-binding cassette transporter A7 in cholesterol homeostasis and host defense system. J Atheroscler Thromb. 2011; 18 (4) 274-281
45 Ikeda Y, Abe-Dohmae S, Munehira Y et al.. Posttranscriptional regulation of human ABCA7 and its function for the apoA-I-dependent lipid release. Biochem Biophys Res Commun. 2003; 311 (2) 313-318
46 Langmann T, Mauerer R, Zahn A et al.. Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin Chem. 2003; 49 (2) 230-238
47 Jehle A W, Gardai S J, Li S et al.. ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages. J Cell Biol. 2006; 174 (4) 547-556
48 Liang Y, Buckley T R, Tu L, Langdon S D, Tedder T F. Structural organization of the human MS4A gene cluster on chromosome 11q12. Immunogenetics. 2001; 53 (5) 357-368
49 Tateno H, Li H, Schur M J et al.. Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity. Mol Cell Biol. 2007; 27 (16) 5699-5710
50 Crocker P R, Paulson J C, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007; 7 (4) 255-266
51 Dustin M L, Olszowy M W, Holdorf A D et al.. A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell. 1998; 94 (5) 667-677
52 Lynch D K, Winata S C, Lyons R J et al.. A cortactin-CD2-associated protein (CD2AP) complex provides a novel link between epidermal growth factor receptor endocytosis and the actin cytoskeleton. J Biol Chem. 2003; 278 (24) 21805-21813
53 Pimplikar S W, Nixon R A, Robakis N K, Shen J, Tsai L H. Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J Neurosci. 2010; 30 (45) 14946-14954
54 McGeer E G, McGeer P L. Innate immunity in Alzheimer's disease: a model for local inflammatory reactions. Mol Interv. 2001; 1 (1) 22-29
55 Bates K A, Verdile G, Li Q X et al.. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry. 2009; 14 (5) 469-486
56 Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell. 2004; 3 (4) 169-176
57 Rowe J A, Moulds J M, Newbold C I, Miller LHP. P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1. Nature. 1997; 388 (6639) 292-295
58 Dietschy J M, Turley S D. Cholesterol metabolism in the brain. Curr Opin Lipidol. 2001; 12 (2) 105-112
59 Puglielli L, Tanzi R E, Kovacs D M. Alzheimer's disease: the cholesterol connection. Nat Neurosci. 2003; 6 (4) 345-351
60 Miwa Y, Takiuchi S, Kamide K et al.. Insertion/deletion polymorphism in clusterin gene influences serum lipid levels and carotid intima-media thickness in hypertensive Japanese females. Biochem Biophys Res Commun. 2005; 331 (4) 1587-1593
61 Ishikawa Y, Akasaka Y, Ishii T et al.. Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta. Arterioscler Thromb Vasc Biol. 1998; 18 (4) 665-672
62 Tanaka N, Abe-Dohmae S, Iwamoto N, Yokoyama S. Roles of ATP-binding cassette transporter A7 in cholesterol homeostasis and host defense system. J Atheroscler Thromb. 2011; 18 (4) 274-281
63 Mack J T, Townsend D M, Beljanski V, Tew K D. The ABCA2 transporter: intracellular roles in trafficking and metabolism of LDL-derived cholesterol and sterol-related compounds. Curr Drug Metab. 2007; 8 (1) 47-57
64 Brody D L, Magnoni S, Schwetye K E et al.. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science. 2008; 321 (5893) 1221-1224
65 Shankar G M, Li S, Mehta T H et al.. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008; 14 (8) 837-842
66 Selkoe D J. Alzheimer's disease. Cold Spring Harb Perspect Biol. 2011; 3 (7) pii: a004457
67 Bartl M M, Luckenbach T, Bergner O, Ullrich O, Koch-Brandt C. Multiple receptors mediate apoJ-dependent clearance of cellular debris into nonprofessional phagocytes. Exp Cell Res. 2001; 271 (1) 130-141
68 Bell R D, Sagare A P, Friedman A E et al.. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007; 27 (5) 909-918
69 Stevens B, Allen N J, Vazquez L E et al.. The classical complement cascade mediates CNS synapse elimination. Cell. 2007; 131 (6) 1164-1178
70 Rademakers R, Rovelet-Lecrux A. Recent insights into the molecular genetics of dementia. Trends Neurosci. 2009; 32 (8) 451-461
71 Rohrer J D, Guerreiro R, Vandrovcova J et al.. The heritability and genetics of frontotemporal lobar degeneration. Neurology. 2009; 73 (18) 1451-1456
72 van der Zee J, Sleegers K, Van Broeckhoven C. Invited article: the Alzheimer disease-frontotemporal lobar degeneration spectrum. Neurology. 2008; 71 (15) 1191-1197
73 Renton A E, Majounie E, Waite A et al.. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011; 72 (2) 257-268
74 DeJesus-Hernandez M, Mackenzie I R, Boeve B F et al.. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011; 72 (2) 245-256
75 Ballatore C, Lee V M, Trojanowski J Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007; 8 (9) 663-672
76 Chen-Plotkin A S, Lee V M, Trojanowski J Q. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol. 2010; 6 (4) 211-220
77 Mackenzie I R, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010; 9 (10) 995-1007
78 Urwin H, Josephs K A, Rohrer J D FReJA Consortium et al. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol. 2010; 120 (1) 33-41
79 Coppola G, Karydas A, Rademakers R et al.. Gene expression study on peripheral blood identifies progranulin mutations. Ann Neurol. 2008; 64 (1) 92-96
80 Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology. 2008; 71 (16) 1235-1239
81 Sleegers K, Brouwers N, Van Damme P et al.. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol. 2009; 65 (5) 603-609
82 Geser F, Martinez-Lage M, Robinson J et al.. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol. 2009; 66 (2) 180-189
83 Barmada S J, Skibinski G, Korb E, Rao E J, Wu J Y, Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci. 2010; 30 (2) 639-649
84 Weihl C C. Valosin containing protein associated fronto-temporal lobar degeneration: clinical presentation, pathologic features and pathogenesis. Curr Alzheimer Res. 2011; 8 (3) 252-260
85 Urwin H, Ghazi-Noori S, Collinge J, Isaacs A. The role of CHMP2B in frontotemporal dementia. Biochem Soc Trans. 2009; 37 (Pt 1) 208-212
86 Lee J A, Liu L, Gao F B. Autophagy defects contribute to neurodegeneration induced by dysfunctional ESCRT-III. Autophagy. 2009; 5 (7) 1070-1072
87 Deng H X, Chen W, Hong S T et al.. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011; 477 (7363) 211-215
88 Van Deerlin V M, Sleiman P M, Martinez-Lage M et al.. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet. 2010; 42 (3) 234-239
89 Finch N, Carrasquillo M M, Baker M et al.. TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology. 2011; 76 (5) 467-474
90 Bonifati V. Recent advances in the genetics of dementia with Lewy bodies. Curr Neurol Neurosci Rep. 2008; 8 (3) 187-189
91 Clark L N, Kartsaklis L A, Wolf Gilbert R et al.. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol. 2009; 66 (5) 578-583
92 Brown K, Mastrianni J A. The prion diseases. J Geriatr Psychiatry Neurol. 2010; 23 (4) 277-298
93 Mead S, Poulter M, Uphill J et al.. Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol. 2009; 8 (1) 57-66
94 Angot E, Steiner J A, Hansen C, Li J Y, Brundin P. Are synucleinopathies prion-like disorders?. Lancet Neurol. 2010; 9 (11) 1128-1138
95 Kim J, Holtzman D M. Medicine. Prion-like behavior of amyloid-beta. Science. 2010; 330 (6006) 918-919
96 Frost B, Diamond M I. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010; 11 (3) 155-159
97 Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser M G. CADASIL. Lancet Neurol. 2009; 8 (7) 643-653
98 Ross C A, Tabrizi S J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011; 10 (1) 83-98
99 Wild E J, Mudanohwo E E, Sweeney M G et al.. Huntington's disease phenocopies are clinically and genetically heterogeneous. Mov Disord. 2008; 23 (5) 716-720
100 Stevanin G, Brice A. Spinocerebellar ataxia 17 (SCA17) and Huntington's disease-like 4 (HDL4). Cerebellum. 2008; 7 (2) 170-178
101 Garcia-Arocena D, Hagerman P J. Advances in understanding the molecular basis of FXTAS. Hum Mol Genet. 2010; 19 (R1) R83-R89
102 Leehey M A. Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment. J Investig Med. 2009; 57 (8) 830-836

Henry L. PaulsonM.D. Ph.D.

Professor of Neurology, Department of Neurology, University of Michigan

4001 BSRB, 109 Zina Pitcher Place, Ann Arbor, MI 48109

eMail: henryp@umich.edu